October 21, 2013
1 min read

Study links genetic variants to poor outcomes after anti-VEGF treatment for AMD

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Variants in genes connected to age-related macular degeneration were associated with poor visual outcomes after treatment with ranibizumab or bevacizumab, according to a study.

The prospective study included 224 patients with neovascular AMD who underwent intravitreal injections of 0.5 mg Lucentis (ranibizumab, Genentech) or 1.25 mg Avastin (bevacizumab, Genentech).

Patients underwent three monthly injections and as-needed injections for an additional 9 months; patients received an average of 6.4 injections.

Investigators examined the influence of 17 single nucleotide polymorphisms (SNPs) in known AMD risk-associated genes on mean change in ETDRS visual acuity at 12 months.

The mean change in visual acuity at 12 months was a gain of 3.2 lines.

The AA genotype at the rs11200638 SNP on the HTRA1 promoter gene and GG genotype at rs10490924 (A69S) in LOC387715/ARMS2 correlated significantly with poor visual acuity outcome at 12 months after multiple correction (P = .001 and P = .002, respectively).

Patients with the AA genotype at the rs11200638 SNP on HTRA1 lost a mean 2.9 letters. Patients with the AG or GG genotypes at the same SNP gained a mean of 5.1 letters. The difference was statistically significant (P = .001).

Disclosure: The study authors have no relevant financial disclosures.